Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
BKK:JSP's PEG Ratio is ranked worse than 51.58% of 789
companies
in the Consumer Packaged Goods industry
Industry Median: 1.29
vs BKK:JSP: 1.42
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
JSP Pharmaceutical Manufacturing (Thailand) PCL PEG Ratio Related Terms
JSP Pharmaceutical Manufacturing (Thailand) PCL PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSP Pharmaceutical Manufacturing (Thailand) PCL PEG Ratio Chart
JSP Pharmaceutical Manufacturing (Thailand) PCL Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JSP Pharmaceutical Manufacturing (Thailand) PCL PEG Ratio vs Consumer Packaged Goods Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) has a PEG Ratio of 1.42 as of Jul. 16, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. This is near median its historical median of 1.46. Over the past decade, JSP Pharmaceutical Manufacturing (Thailand) PCL's PEG Ratio has ranged from 1.41 to 1.56. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #407 out of 789 companies in the Consumer Packaged Goods industry, placing it in the top 51.6%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's PEG Ratio too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current PEG Ratio of 1.42 is near median its 10-year median of 1.46. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 1.56. The Consumer Packaged Goods industry median PEG Ratio is 1.29. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 1.42 is 10.1% above this industry median. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #407 out of 789 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's PEG Ratio compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #407 out of 789 companies for PEG Ratio. This places JSP Pharmaceutical Manufacturing (Thailand) PCL in the lower half of its industry. The industry median PEG Ratio is 1.29. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 1.42 is 10.1% above this benchmark. Historically, JSP Pharmaceutical Manufacturing (Thailand) PCL's own PEG Ratio has ranged from 1.41 to 1.56 over the past decade. While the company's 10-year median is 1.46 vs. the industry median of 1.29, JSP Pharmaceutical Manufacturing (Thailand) PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Consumer Packaged Goods company?
The median PEG Ratio among Consumer Packaged Goods companies is 1.29, based on 789 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JSP Pharmaceutical Manufacturing (Thailand) PCL's current PEG Ratio of 1.42 is 10.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. For the Consumer Packaged Goods industry, the median PEG Ratio is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current PEG Ratio is 1.42, which is near median its own 10-year median of 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿3.16, compared to a current price of ฿1.78 — trading 43.7% below its estimated fair value. The current PEG Ratio is 1.42, which is near median its 10-year median of 1.46 and 10.1% above the Consumer Packaged Goods industry median of 1.29. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP), the current PEG Ratio is 1.42 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.78 is trading 43.7% below its estimated GF Value™ of ฿3.16.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Significantly Undervalued.
Key valuation signals for BKK:JSP:
PEG Ratio: 1.42 (near median its 10-year median of 1.46)
GF Value™: ฿3.16 vs. price of ฿1.78 (43.7% below fair value)
Industry Position: 10.1% above the Consumer Packaged Goods median (#407 of 789)
No single metric tells the full story. See the BKK:JSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL Business Description
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
80GF Score
Get the complete analysis for BKK:JSP
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP has been successfully added to your 
